Sort
4,870 grants matching “glp 1”
Functional Studies of the Incretin GIP Receptor in Adipocytes
$254,250Timothy E McGraw · Weill Medical Coll Of Cornell Univ · R56 · FY2017 · DK
Control of primordial germ cell quiescence by niche basement membrane and Notch signaling
$254,250Jeremy Franklin Nance · New York University School Of Medicine · R21 · FY2022 · HD
Molecular Basis of Antidiabetogenic Hormone Action
$254,246George G Holz · Upstate Medical University · R01 · FY2008 · DK
Parenteral Nutrition: Intestinal Metabolism/Adaptation
$254,088Denise M Ney · University Of Wisconsin-Madison · R01 · FY2006 · DK
The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers
$253,665Eric G. Devine · Boston Medical Center · R21 · FY2019 · AA
Potential Mechanisms of Glucagon-like peptide-1 in Fatty Liver Disease
$253,399Frank A. Anania · Emory University · R01 · FY2008 · DK
Biorepository, Pathology, and Immune Monitoring Core
$253,376Kent J. Weinhold · Duke University · P50 · FY2022 · CA
Mechanisms of Intestinal Stem Cell Expansion Following Resection
$253,238Michael A Helmrath · Cincinnati Childrens Hosp Med Ctr · R01 · FY2013 · DK
Phase 2A Study of Exendin for the Treatment of Congenital Hyperinsulinism
$252,794Diva Del Carmen De Leon · Children'S Hosp Of Philadelphia · R01 · FY2013 · FD
Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track)
$252,416Zhiyong Yang · Fzata, Inc. · R44 · FY2021 · DK
Preclinical studies to validate the efficacy of novel mechanism-of-action small molecule inhibitors to treat Duchenne muscular dystrophy
$252,131Harshini Neelakantan · Ridgeline Therapeutics, Llc · R41 · FY2019 · AR
Novel non-narcotic analgesic for acute and chronic pain
$252,125Nicolas Guillermo Bazan · South Rampart Pharma, Llc · R42 · FY2020 · NS
Hosted Commercial In-Life Data Collection and Management System for the National Toxicology Program (Subproject 1 (Support for Cancer Research by NTP)
$251,971David Wheeler · Instem Lss (North America) Limited · N01 · FY2021 · ES
Carbon Monoxide Delivery in Sepsis and Acute Lung Injury
$251,354Augustine M Choi · Brigham And Women'S Hospital · P01 · FY2012 · HL
Neuroprotective role of GLP-1 receptor agonists (Neurodegenerative disorders & Alzheimer's disease)
$251,332Nigel H. Greig · National Institute On Aging · ZIA · FY2022 · AG
CORE--RETROVIRAL VECTOR
$251,290Fred Hutchinson Cancer Research Center · P01 · FY2000 · AI
Phase II trial of extended release exenatide (Bydureon) and teplizumab in patients with new onset Type 1 Diabetes.
$251,250Kevan C Herold · Yale University · R34 · FY2016 · AI
GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration
$251,250Gustavo Adolfo Angarita · Yale University · R21 · FY2017 · DA
Regulatory Compliance Core
$251,181Jacob Koster · Boston University Medical Campus · UC7 · FY2017 · AI
Potential Mechanisms of Glucagon-like peptide-1 in Fatty Liver Disease
$250,865Frank A. Anania · Emory University · R01 · FY2010 · DK
Fluorescence Image-Guided Near Infrared (NIR) Photodynamic Therapy (PDT) Agent
$250,569Manivannan Ethirajan · Photolitec, Llc · R42 · FY2013 · CA
CORE--PHARMACOKINETICS /PREFORMULATION
$250,404University Of Arizona · U19 · FY2001 · CA
CORE--PHARMACOKINETICS /PREFORMULATION
$250,404University Of Arizona · U19 · FY2002 · CA
Development of an oral therapeutic to mimic the anti-diabetic effects of gastric bypass surgery
$250,402Jerzy Szewczyk · Biokier, Inc. · R44 · FY2018 · DK
Biorepository, Pathology, and Immune Monitoring Core
$250,310Kent J. Weinhold · Duke University · P50 · FY2023 · CA